Uncategorized
Gene Therapy Partners Aim to Enhance Protein Expression
Gene Therapy Partners Aim to Enhance Protein Expression
Circio Holding and Avenue Biosciences agreed to a research collaboration designed to combine their synergistic technologies to improve long-term expression of secreted proteins, relevant for treatment of a broad range of diseases.
Secreting proteins from cells into surrounding tissue, or into circulation, opens new treatment opportunities beyond classical gene therapy for monogenic disease, say scientists from both companies. Circio maintains that its circVec platform drives higher and more durable protein expression, and a spokesperson from Avenue Biosciences explains that its protein engineering technology improves protein secretion from cells by screening thousands of signal peptide-protein combinations.
Circio and Avenue will jointly explore whether the two technologies in combination can act synergistically to improve the production and secretion of proteins, including antibodies, for the treatment of genetic and chronic diseases.
“Many gene therapies are limited by insufficient protein expression, driving high doses, manufacturing complexity, and cost. The secretory pathway—the cellular machinery that produces and exports proteins—is a largely underutilized engineering opportunity. By combining Circio’s durable circular RNA expression with our technology, we aim to increase protein output per dose and ultimately help more patients benefit from life-changing genetic medicines,” says Avenue Biosciences CEO Tero-Pekka Alastalo, MD, PhD.
In the collaboration, Avenue Biosciences will deploy its protein engineering platform to identify signal peptides that enable improved secretion of therapeutic proteins expressed by circVec. The initial screening will be performed by Avenue Biosciences, followed by further in vitro and in vivo testing by Circio.
“A significant proportion of therapeutically relevant payloads for circVec are secreted proteins,” adds Victor Levitsky, PhD, CSO of Circio. “With the Avenue platform, we will test how signal peptide optimization can enhance secretion of proteins and thereby open novel opportunities for the circVec platform in genetic and chronic disease. This collaboration is an important addition to our pre-clinical development strategy of testing circVec in multiple settings through R&D partnerships to broadly explore the range of therapeutic options available for our unique circular RNA expression technology.”
The post Gene Therapy Partners Aim to Enhance Protein Expression appeared first on GEN – Genetic Engineering and Biotechnology News.
Uncategorized
New webinar: Tackling drug discovery challenges in cancer research

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.
You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.
Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.
Q&A with the speakers follows the presentations.
The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).
Uncategorized
Psilocybin proves promising in neuropathic pain mouse study
Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.
Uncategorized
New Spectrometry Technique Could Aid Formulation Development
New Spectrometry Technique Could Aid Formulation Development
A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.
According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.
“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”
Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.
The challenge is understanding the link between these things within a heterogeneous sample, he says.
To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.
He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.
Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.
Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.
The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.
-
Uncategorized8 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion
-
Endpoints News8 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized7 months agoOptical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells
-
Uncategorized6 months ago
Relay’s PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
-
Uncategorized5 months ago
Hybrid solid−liquid optics enable scalable, high-resolution light-sheet microscopy across diverse immersion media
-
Fierce Biotech8 months ago
Scientists turn pig semen extract into eye drops that kill cancer in mice
-
Nature Biotechnology8 months ago
Sustained nitric oxide production by engineered E. coli remodels the tumor microenvironment and potentiates immunotherapy
-
BioPharma Dive – AI / Data8 months agoAstraZeneca lung drug gets ‘surprise’ win in COPD trials
Scan to Read